Literature DB >> 22678422

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.

Anna Flammiger1, Walter Fiedler, Ulrike Bacher, Carsten Bokemeyer, Marion Schneider, Mascha Binder.   

Abstract

Macrophage activation syndrome (MAS) is a life-threatening disease with sustained activation of inflammatory cells and release of proinflammatory TNF-α. Under physiological conditions, TNF-α initiates a negative feedback mechanism, mediated by shedded, soluble TNF receptor ectodomains, eventually limiting the inflammatory reaction. Here, we report on a 27-year-old critically ill patient with refractory MAS and an insufficient negative feedback regulation, resulting in an overwhelming inflammatory response. A personalized treatment with soluble TNF receptor etanercept resulted in a durable remission. Further studies are warranted to establish whether the TNF cytokine profile may help to successfully guide patient selection for biological therapies.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678422     DOI: 10.1159/000338179

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  11 in total

1.  Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency.

Authors:  Timothy J Franxman; Laura E Howe; James R Baker
Journal:  J Clin Immunol       Date:  2014-07-27       Impact factor: 8.317

Review 2.  Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Authors:  Courtney Crayne; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

3.  The inflammatory twitch as a general strategy for controlling the host response.

Authors:  Joshua J Pothen; Matthew E Poynter; Jason H T Bates
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

4.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

Review 5.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

Review 6.  The Immunology of Macrophage Activation Syndrome.

Authors:  Courtney B Crayne; Sabrin Albeituni; Kim E Nichols; Randy Q Cron
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

7.  The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.

Authors:  Fernanda I Arnaldez; Steven J O'Day; Charles G Drake; Bernard A Fox; Bingqing Fu; Walter J Urba; Vincenzo Montesarchio; Jeffrey S Weber; Haiming Wei; Jon M Wigginton; Paolo Antonio Ascierto
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 8.  Cytokine release syndrome: grading, modeling, and new therapy.

Authors:  Delong Liu; Juanjuan Zhao
Journal:  J Hematol Oncol       Date:  2018-09-24       Impact factor: 17.388

Review 9.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

Review 10.  Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Authors:  Bingwen Liu; Min Li; Zhiguang Zhou; Xuan Guan; Yufei Xiang
Journal:  J Autoimmun       Date:  2020-04-10       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.